ロード中...
Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3833260/ https://ncbi.nlm.nih.gov/pubmed/22712793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2165/1163018-S0-000000000-00000 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|